On July 28, 2023, the FDA approved RiVive™ (naloxone hydrochloride) 3 mg nasal spray for use without a prescription. It is the second over the counter (OTC) naloxone product approved for the emergency treatment of known or suspected opioid overdose. Naloxone rapidly reverses the effects of opioids, and prompt administration of the drug can rescue an individual suffering an opioid overdose from death. Studies showed that RiVive™ reaches the bloodstream at a level comparable to that achieved by an approved prescription naloxone product, and studied consumers demonstrated an understanding of how to use the drug safely and effectively without a health care professionals’ supervision. Drug overdose is a major public health issue in the U.S., and the OTC availability of naloxone products may help increase access and protect the health of consumers. There are no risks when administering naloxone to individuals who haven’t taken opioids, so it can be administered whenever an opioid overdose is suspected. The pricing and availability of RiVive™ is not yet known but is anticipated for early 2024 as determined by the manufacturer, Harm Reduction Therapeutics, Inc. Harm Reduction Therapeutics, Inc. will also make at least 200,000 doses available free of charge to consumers.